
Ȳ¹Ý
- ÀúÀÚ(±Û)±Ç¿À¿õ À¯È£¹Î À̼ºÃ¶
- ÃâÆÇ»çµµ¼ÃâÆÇ Áø±âȹ
- ¹ßÇàÀÏ2015-12-15
Àü ´ëÇѾȰúÇÐȸÀå, ¸Á¸· ºÐ¾ß ±ÇÀ§ÀÚ,anti-VEGF ¾à¹° ÁÖ»ç Ä¡·á ±¹³» ÃÖÃÊ µµÀÔ
¾È°úÇÐȸÀåÀÌÀÚ ¿¬¼¼´ëÇб³ Àǰú´ëÇÐ ¸í¿¹±³¼öÀÌ´Ù. ¿¬¼¼´ë ¼¼ºê¶õ½º ¾È¡¤À̺ñÀÎÈİúº´¿øÀå°ú ¼¼°èȲ¹ÝÇÐȸ ±¹Á¦À§¿øÀå, Çö ´©³×¾È°úº´¿øÀåÀ» ¿ªÀÓÇß´Ù.
ƯÈ÷ ´ç´¢¸Á¸·º´Áõ Ä¡·á ºÐ¾ß¿¡ ¡®±¤¹üÀ§ ¸Á¸·Áõ½Ä Á¦°Å¼ú¡¯°ú Ȳ¹Ýº¯¼ºÀ¸·Î »õ·Î ¸¸µé¾îÁø Ç÷°üÁ¶Á÷À» ã¾Æ ¾ø¾Ö´Â ±¤¿ªÇÐ Ä¡·á ¹× Ç×ü ÁÖ»ç Ä¡·á¸¦ ±¹³» ÃÖÃÊ ½ÃµµÇßÀ¸¸ç, ºÒÄ¡º´À¸·Î ¾Ë·ÁÁø Á¤¸ÆÇ÷°üÆó¼âÁõ Ä¡·á¿¡ ¡®Ç÷Àü¿ëÇØÁ¦ Á÷Á¢ ÁÖÀÔ¼ú¡¯À» ¾Æ½Ã¾Æ ÃÖÃÊ·Î ½ÃÇàÇÏ´Â µî ¾È°úÇÐ ¹ßÀü¿¡ ¸¹Àº ³ë·ÂÀ» ÇÏ´Â ¸íÀÇ·Î ¾Ë·ÁÁ® ÀÖ´Ù.
Á¦ ¸ñ | Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study*): A 12-month, randomized, controlled, double-masked, multicenter phase II study. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2010 | ¹ßÇ¥Áö | Diabetes Care |
Á¦ ¸ñ | Concentration of Cytokines in the Aqueous Humor of Patients with Naïve, Recurrent and Regressed CNV associated with AMD after Bevacizumab Treatment | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2009 | ¹ßÇ¥Áö | Retina |
Á¦ ¸ñ | Short-Term Safety and Efficacy of a Single Intravitreal Bevacizumab Injection for the Management of Polypoidal Choroidal Vasculopathy. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2009 | ¹ßÇ¥Áö | Ophthalmologica |
Á¦ ¸ñ | Estimated Prevalence and Risk Factor for Age-related Maculopathy. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2008 | ¹ßÇ¥Áö | Yonsei Med J |
Á¦ ¸ñ | Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2008 | ¹ßÇ¥Áö | Jpn J Ophthalmol |
Á¦ ¸ñ | Polypoidal Choroidal Vasculopathy in Korean Patients with Large Submacular Hemorrhage | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2007 | ¹ßÇ¥Áö | Yonsei Med J |
Á¦ ¸ñ | Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula. | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2004 | ¹ßÇ¥Áö | Ophthalmologica |
[ºÐ¾ß] ¿¬·É°ü·ÃȲ¹Ýº¯¼º[¾÷Àû] 2006 ¸Á¸·ÇÐȸ Çмú»ó ¼ö»ó 2010 Çѱ¹¾È°úÇÐȸ Çѱæ Çмú»ó ¼ö»ó
¾ÈÀüÇϰí Áø½ÇµÈ Áø·á. ȯÀÚ¸¦ Á¸ÁßÇÏ´Â ¸¶À½
ÀηùÀÇ »ýÁ¸ ¿¬·ÉÀÌ Á¡Â÷ ´Ã¾î³ª°í °æÁ¦ÀûÀ¸·Î ¹ß´ÞÇÔ¿¡ µû¶ó ÀÏ»ó »ýȰÀ» ºñ·ÔÇÏ¿© ¸ð´ø Ȱµ¿ ¿µ¿ª¿¡¼ ½Ã·ÂÀÇ Á߿伺Àº Á¡Á¡ ³ô¾ÆÁö°í ÀÖ´Ù. ¼¼°èÀûÀÎ Ãß¼¼¸¦ º¸¸é ¾È°ú ºÐ¾ßÀÇ ¼öÁØÀº ±Þ¼ºÀåÀ» ÇßÀ¸³ª ¾ÆÁ÷ ºÎÁ·ÇÑ ºÎºÐ ÁßÀÇ ÇϳªÀÎ ½À¼ºÈ²¹Ýº¯¼º°ú ´ç´¢È²¹ÝºÎÁ¾ µîÀÌ ³Ä¡º´À¸·Î ¹®Á¦°¡ µÇ°í ÀÖ´Ù. ½À¼ºÈ²¹Ýº¯¼º°ú ´ç´¢È²¹ÝºÎÁ¾Àº Ä¡·á ½Ã±â¸¦ ³õÄ¡¸é ±× ÈÄ¿¡ ¾Æ¹«¸® Àß Ä¡·á¸¦ ÇÏ¿©µµ ½Ã·Â ¼Õ»óÀ» ȸº¹ÇÏ±â ¾î·Æ´Ù. ¾È±¸³» anti-VEGFÁ¦Á¦´Â ÃÖ±Ù ±¹³»¿Ü¿¡¼ »õ·Î¿î Á¦Ç°µéÀÌ ¿©·µ Ãâ½ÃµÇ¾î Ȱ¹ßÇÏ°Ô ¾²À̰í ÀÖÀ¸¸ç ±× È¿°ú´Â ºñ±³Àû ÁÁÀº ÆíÀÌÁö¸¸ 1-3´Þ¸¶´Ù ¿©·¯¹ø ¹øº¹ Åõ¿©¸¦ °è¼Ó ÇØ¾ßÇÏ´Â ¾î·Á¿òÀÌ ³²¾Æ ÀÖ´Ù. ÃÖ±Ù Çѹø ÁÖ»ç Åõ¿©·Î Àå±â°£ È¿°ú¸¦ º¼ ¼ö ÀÖ´Â ¾àÁ¦ÀÇ ÃâÇöÀÌ ¿¹°ßµÇ°í ¾È±¸³»Áֻ簡 ¾Æ´Ñ °æ±¸Åõ¿©·Î Ä¡·á°¡ °¡´ÉÇÑ Â÷¼¼´ë ¾àÁ¦ °³¹ß¿¡ ÁýÁßÇϰí ÀÖÀ¸¹Ç·Î ÀæÀº ¾È±¸³»ÁÖ»ç Ä¡·áÀÇ ¾î·Á¿ò¿¡¼ ÇØ¹æµÇ´Â ½Ã±â°¡ °ð ¿Ã °ÍÀ¸·Î ±â´ëÇÑ´Ù.
´©³×¾È°úº´¿øÀº ¸íÀǸ¦ ºñ·Ô, ¿ì¼öÇÑ ÀÇ·áÁø°ú ÷´Ü ½Ã¼³À» °®Ãß°í ÀÖ¾î °¢¸·, ¸Á¸·, ¹é³»Àå, ³ì³»Àå, »ç½Ã, ½Ã·Â±³Á¤, ¾È¼ºÇü µî ´«¿¡¼ ¹ß»ýÇÒ ¼ö ÀÖ´Â ¸ðµç ÁúȯÀ» ÇÑ °÷¿¡¼ Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù. ³²¾çÁÖ ´©³×¾È°úº´¿øÀº ±âº» °Ë»ç½Ç ¹× Á¤¹Ð °Ë»ç½Ç, °ÇÁ¶ÁõŬ¸®´Ð, óġ½Ç, ÁÖ»ç½ÇÀº ¹°·Ð ·»Áî½Ç, ¼ö¼ú¼¾ÅÍ, º´µ¿±îÁö °®Ãß°í ÀÖ¾î ü°èÀûÀ¸·Î Áø·á¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.
°æ±âµµ ³²¾çÁÖ½Ã ÇØ¹Ð¿¹´ç1·Î 28 ÁøÁ¢³óÇù 4Ãþ